Collegium Pharmaceutical COLL
NASDAQ COLL
$27.64 -1.10 (-3.84%)
At close: Aug 20, 2026 · 12:57 PM UTC

Collegium Pharmaceutical (COLL) Gains from Investment Securities (2024 - 2025)

Collegium Pharmaceutical (COLL) posted quarterly Gains from Investment Securities of -$19000.0 for Q4 2025, up 99.35% year-over-year from -$9531.1 in Q4 2024, and little changed quarter-over-quarter from -$19000.0 in Q3 2025.

Collegium Pharmaceutical (COLL) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Collegium Pharmaceutical's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at -$19000.0 for Q4 2025.

  • In Q4 2025, Gains from Investment Securities rose 99.35% year-over-year to -$19000.0; the TTM figure through Mar 2026 stood at -$396000.0 (up 89.3% YoY), while the FY2025 annual figure was -$1.2 million, up 59.44% from the prior year.
  • Gains from Investment Securities for Q4 2025 stood at -$19000.0, roughly flat from -$19000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was -$19000.0 in Q3 2025, with the low at -$2.9 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 43.96 Bn 43.00 Bn -
2 Teva Pharmaceutical Industries 43.23 Bn 39.58 Bn 2.15 Bn
3 Zoetis 31.76 Bn 30.08 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.68 Bn 22.88 Bn 5.10 Bn
5 United Therapeutics 22.27 Bn 19.61 Bn 683.80 Mn
6 Viatris 18.69 Bn 17.81 Bn 1.46 Bn
7 Neurocrine Biosciences 15.56 Bn 15.17 Bn 935.80 Mn
8 Elanco Animal Health 11.78 Bn 11.25 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.13 Bn 9.97 Bn -
10 Collegium Pharmaceutical 897.05 Mn 747.74 Mn 110.29 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -19,000.00
Dec 31, 2025 -19,000.00
Sep 30, 2025 -19,000.00
Sep 30, 2025 -19,000.00
Jun 30, 2025 -358,000.00
Jun 30, 2025 -358,000.00
Mar 31, 2025 -786,000.00
Mar 31, 2025 -786,000.00
Dec 31, 2024 -2.91 Mn
Dec 31, 2024 -2.91 Mn